PL354528A1 - Podstawione indole przeznaczone do modulowania aktywności NFkB - Google Patents

Podstawione indole przeznaczone do modulowania aktywności NFkB

Info

Publication number: PL354528A1
Authority: PL; Poland
Prior art keywords: substituted indoles; nfkb activity; modulating nfkb; modulating; activity
Prior art date: 1999-10-26

Application number

PL00354528A

Other languages

English (en)

Other versions

PL200115B1 (pl

Inventor

Olaf Ritzeler

Hans Ulrich Stilz

Bernhard Neises

Gerhard Jaehne

Jorg Habermann

Original Assignee

Aventis Pharma Deutschland Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-26

Filing date

2000-10-17

Publication date

2004-01-26

2000-10-17 Application filed by Aventis Pharma Deutschland Gmbh filed Critical Aventis Pharma Deutschland Gmbh

2004-01-26 Publication of PL354528A1 publication Critical patent/PL354528A1/pl

2008-12-31 Publication of PL200115B1 publication Critical patent/PL200115B1/pl

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Neurosurgery (AREA)
Rheumatology (AREA)
Hematology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
AIDS & HIV (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

PL354528A 1999-10-26 2000-10-17 Nowe podstawione indole, lek zawierający nowe podstawione indole oraz zastosowanie nowych podstawionych indoli PL200115B1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19951360A DE19951360A1 (de)	1999-10-26	1999-10-26	Substituierte Indole

Publications (2)

Publication Number	Publication Date
PL354528A1 true PL354528A1 (pl)	2004-01-26
PL200115B1 PL200115B1 (pl)	2008-12-31

Family

ID=7926798

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL354528A PL200115B1 (pl)	1999-10-26	2000-10-17	Nowe podstawione indole, lek zawierający nowe podstawione indole oraz zastosowanie nowych podstawionych indoli

Country Status (31)

Country	Link
US (3)	US20030119820A1 (pl)
EP (1)	EP1261601B1 (pl)
JP (1)	JP3843012B2 (pl)
KR (1)	KR100795709B1 (pl)
CN (1)	CN1172929C (pl)
AT (1)	ATE437867T1 (pl)
AU (1)	AU781553B2 (pl)
BR (1)	BR0015026B1 (pl)
CA (1)	CA2389165C (pl)
CY (1)	CY1110521T1 (pl)
CZ (1)	CZ304885B6 (pl)
DE (2)	DE19951360A1 (pl)
DK (1)	DK1261601T3 (pl)
EE (1)	EE05036B1 (pl)
ES (1)	ES2329871T3 (pl)
HR (1)	HRP20020357B1 (pl)
HU (1)	HU229215B1 (pl)
IL (2)	IL149272A0 (pl)
ME (1)	ME00434B (pl)
MX (1)	MXPA02003998A (pl)
NO (1)	NO323952B1 (pl)
NZ (1)	NZ518587A (pl)
PL (1)	PL200115B1 (pl)
PT (1)	PT1261601E (pl)
RS (1)	RS50424B (pl)
RU (1)	RU2255087C2 (pl)
SI (1)	SI1261601T1 (pl)
SK (1)	SK287116B6 (pl)
TR (1)	TR200201144T2 (pl)
WO (1)	WO2001030774A1 (pl)
ZA (1)	ZA200203204B (pl)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL209572B1 (pl)	1999-12-24	2011-09-30	Aventis Pharma Ltd	Kompozycja farmaceutyczna zawierająca podstawione azaindole, podstawione azaindole i ich farmaceutyczne zastosowania
DE60133758T2 (de)	2000-10-26	2009-07-02	Amgen Inc., Thousand Oaks	Antiphlogistische mittel
GB0115109D0 (en)	2001-06-21	2001-08-15	Aventis Pharma Ltd	Chemical compounds
EP2335700A1 (en) *	2001-07-25	2011-06-22	Boehringer Ingelheim (Canada) Ltd.	Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP4448327B2 (ja) *	2001-08-13	2010-04-07	イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー	新規置換１ｈ−ジヒドロピラゾール、それらの製造および使用
US9248124B2 (en)	2001-11-07	2016-02-02	Millennium Pharmaceuticals, Inc.	Use of inhibitors of IκB kinase for the treatment of cancer
US7176314B2 (en)	2001-12-05	2007-02-13	Amgen, Inc.	Inflammation modulators
DK1474425T3 (da)	2002-01-07	2006-09-25	Eisai Co Ltd	Deazapuriner og anvendelser deraf
AU2003237330A1 (en)	2002-06-06	2003-12-22	Boehringer Ingelheim Pharmaceuticals, Inc.	Substituted 3-amino-thieno[2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
US6974870B2 (en)	2002-06-06	2005-12-13	Boehringer Ingelheim Phamaceuticals, Inc.	Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses
DE10237723A1 (de) *	2002-08-17	2004-07-08	Aventis Pharma Deutschland Gmbh	Verwendung von IKappaB-Kinase Inhibitoren in der Schmerztherapie
US7462638B2 (en) *	2002-08-17	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de) *	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
JP2006512313A (ja)	2002-10-31	2006-04-13	アムジェンインコーポレイテッド	抗炎症剤
US7223785B2 (en)	2003-01-22	2007-05-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
US7098231B2 (en)	2003-01-22	2006-08-29	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
EP1462105A1 (en) *	2003-03-28	2004-09-29	Procorde GmbH	Activation specific inhibitors of NF-kB and method of treating inflammatory processes in cardio-vascular diseases
AU2004230952A1 (en)	2003-04-09	2004-10-28	Millenium Pharmaceuticals, Inc.	Beta-carbolines useful for treating inflammatory disease
US20050004164A1 (en) *	2003-04-30	2005-01-06	Caggiano Thomas J.	2-Cyanopropanoic acid amide and ester derivatives and methods of their use
TWI368508B (en)	2004-02-20	2012-07-21	Boehringer Ingelheim Int	Viral polymerase inhibitors
CA2561859A1 (en)	2004-04-09	2005-11-24	Millennium Pharmaceuticals, Inc.	Beta-carbolines useful for treating inflammatory disease
TWI391387B (zh) *	2004-05-12	2013-04-01	Eisai R&D Man Co Ltd	具有哌啶環之吲哚衍生物
US7425580B2 (en)	2004-05-19	2008-09-16	Wyeth	(Diaryl-methyl)-malononitriles and their use as estrogen receptor ligands
TW200616967A (en)	2004-06-24	2006-06-01	Smithkline Beecham Corp	Novel indazole carboxamides and their use
TW200626142A (en)	2004-09-21	2006-08-01	Glaxo Group Ltd	Chemical compounds
DE102005025225A1 (de)	2005-06-01	2006-12-07	Sanofi-Aventis Deutschland Gmbh	Verfahren zur Herstellung von 2-(2-Amino-pyrimidin-4-yl)-1H-indol-5-carbonsäure-derivaten
US8063071B2 (en)	2007-10-31	2011-11-22	GlaxoSmithKline, LLC	Chemical compounds
AR055343A1 (es)	2005-06-30	2007-08-22	Smithkline Beecham Corp	Derivados de indolcarboxamida inhibidores de quinasas ikk2
WO2007019674A1 (en)	2005-08-12	2007-02-22	Boehringer Ingelheim International Gmbh	Viral polymerase inhibitors
JP2009001495A (ja) *	2005-10-13	2009-01-08	Taisho Pharmaceutical Co Ltd	２−アリール−ベンゾイミダゾール−５−カルボキサミド誘導体
UA95788C2 (en) *	2005-12-15	2011-09-12	Ф. Хоффманн-Ля Рош Аг	Fused pyrrole derivatives
EP2029608A1 (en)	2006-06-06	2009-03-04	Boehringer Ingelheim International GmbH	Substituted 3-amino-thieno[2,3-b] pyridine-2-carboxamide compounds, their preparation and use
JP2010500300A (ja)	2006-08-08	2010-01-07	サノフィ−アベンティス	アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
CN101583598B (zh) *	2007-01-15	2012-09-12	参天制药株式会社	具有IκB激酶β抑制活性的新型吲哚衍生物
AR065804A1 (es)	2007-03-23	2009-07-01	Smithkline Beecham Corp	Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
EP2025674A1 (de)	2007-08-15	2009-02-18	sanofi-aventis	Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US11969501B2 (en)	2008-04-21	2024-04-30	Dompé Farmaceutici S.P.A.	Auris formulations for treating otic diseases and conditions
KR101449785B1 (ko)	2008-04-21	2014-10-14	오토노미, 인코포레이티드	귀 질환 및 병태를 치료하기 위한 귀 조제물
WO2010003624A2 (en)	2008-07-09	2010-01-14	Sanofi-Aventis	Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
KR20110031481A (ko) *	2008-07-14	2011-03-28	산텐 세이야꾸 가부시키가이샤	카르바모일기, 우레이드기 및 치환 옥시기를 갖는 신규 인돌 유도체
MD4009C2 (ro) *	2008-07-15	2010-08-31	Институт Химии Академии Наук Молдовы	Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
BRPI0919282A2 (pt)	2008-10-02	2017-03-28	Asahi Kasei Pharma Corp	composto, composição farmacêutica, inibidor de ikkb, método para inibir ikkb, métodos para prevenir e/ou tratar uma doença ou sintoma associado com nf-kb, uma doença ou sintoma associado com ikkb, e uma doença ou sintoma associado com reação inflamatória aguda ou crônica em mamíferos
DE102008052943A1 (de) *	2008-10-23	2010-04-29	Merck Patent Gmbh	Azaindolderivate
EP2351753B1 (en) *	2008-10-23	2015-02-11	Kabushiki Kaisha Yakult Honsha	PHENANTHROINDOLIZIDINE DERIVATIVE AND NF kB INHIBITOR CONTAINING SAME AS ACTIVE INGREDIENT
WO2010068601A1 (en)	2008-12-08	2010-06-17	Sanofi-Aventis	A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US20110305706A1 (en) *	2009-02-23	2011-12-15	Scott Thomas Brady	Compositions and Methods for Treating a Disease Mediated by Soluble Oligomeric Amyloid Beta
US8354539B2 (en)	2009-03-10	2013-01-15	Glaxo Group Limited	Indole derivatives as IKK2 inhibitors
RU2012111354A (ru)	2009-08-26	2013-10-10	Санофи	Новые кристаллические гидраты фторгликозидов, содержащие их фармацевтические препараты и их использование
WO2011107494A1 (de)	2010-03-03	2011-09-09	Sanofi	Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de)	2010-06-18	2018-01-24	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
TW201215388A (en)	2010-07-05	2012-04-16	Sanofi Sa	(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en)	2010-07-05	2012-04-16	Sanofi Aventis	Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en)	2010-07-05	2012-06-01	Sanofi Sa	Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
KR20130099044A (ko)	2010-08-12	2013-09-05	사노피	２，３디아미노프로피온산 유도체의 에난티오머 형태의 제조 방법
CN102584842A (zh) *	2011-01-17	2012-07-18	北京大学	取代吲哚并内酰胺衍生物的制备及作为抗疟疾剂的用途
EP2683699B1 (de)	2011-03-08	2015-06-24	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de)	2011-03-08	2014-12-24	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683705B1 (de)	2011-03-08	2015-04-22	Sanofi	Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de)	2011-03-08	2015-05-27	Sanofi	Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120052A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de)	2011-03-08	2014-12-24	Sanofi	Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120051A1 (de)	2011-03-08	2012-09-13	Sanofi	Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120053A1 (de)	2011-03-08	2012-09-13	Sanofi	Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de)	2011-03-08	2012-09-13	Sanofi	Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en)	2011-09-12	2013-03-21	Sanofi	6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en)	2011-09-27	2015-10-21	Sanofi	6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2015320341B2 (en)	2014-09-26	2021-05-27	Rajendra Sahai Bhatnagar	Inhibitors of NF kappa-B activity for treatment of diseases and disorders
CN109689027A (zh)	2016-06-29	2019-04-26	奥德纳米有限公司	甘油三酯耳用制剂及其用途
MX2020005515A (es) *	2017-12-19	2020-09-03	Bristol Myers Squibb Co	Compuestos de indol sustituidos con amida, utiles como inhibidores de receptores de tipo toll (tlr).
CN112739365B (zh)	2018-08-10	2025-10-28	糖平制药公司	三肽以及代谢、心血管和炎性病症的治疗
US20210236398A1 (en) *	2020-01-31	2021-08-05	L'oreal	Compositions and methods for hair
FR3107832B1 (fr) *	2020-03-05	2022-04-29	Oreal	Compositions et procédés pour les cheveux

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1994008962A1 (en) *	1992-10-14	1994-04-28	Merck & Co., Inc.	Fibrinogen receptor antagonists
GB9225141D0 (en) *	1992-12-01	1993-01-20	Smithkline Beecham Corp	Chemical compounds
JP3213426B2 (ja) *	1993-02-19	2001-10-02	エーザイ株式会社	６，７−ジヒドロ−５Ｈ−シクロペンタ〔ｄ〕ピリミジン誘導体
IT1271352B (it) *	1993-04-08	1997-05-27	Boehringer Ingelheim Italia	Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
GB9605065D0 (en) *	1996-03-11	1996-05-08	Merck Sharp & Dohme	Therapeutic agents
WO1998005637A1 (de) *	1996-08-01	1998-02-12	Merckle Gmbh	Acylpyrroldicarbonsäuren und acylindoldicarbonsäuren sowie ihre derivate als hemmstoffe der cytosolischen phospholipase a¿2?
FR2751966B1 (fr) *	1996-08-01	1998-10-30	Union Pharma Scient Appl	Nouveaux derives 1,2-diarylindoles, leurs procedes de preparation, et leurs utilisations en therapeutique
CN1246856A (zh) *	1996-11-19	2000-03-08	安姆根有限公司	芳基和杂芳基取代的稠合吡咯抗炎药
BR9814956A (pt) *	1997-11-10	2000-10-03	Bristol Myers Squibb Co	Inibidores de benzotiazol da tirosina cinase de proteìna
NZ506329A (en) *	1998-02-25	2004-01-30	Inst Genetics Llc	Inhibitors of phospholipase enzymes
PL206826B1 (pl) *	1999-06-23	2010-09-30	Sanofi Aventis Deutschland	Podstawione benzimidazole
US7462638B2 (en)	2002-08-17	2008-12-09	Sanofi-Aventis Deutschland Gmbh	Use of IκB-kinase inhibitors in pain therapy
DE10237722A1 (de)	2002-08-17	2004-08-19	Aventis Pharma Deutschland Gmbh	Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
CA2566213A1 (en)	2004-05-12	2005-12-11	Aventis Pharmaceuticals Inc.	Substantially pure 2-{[2-(2-methylamino-pyrimidin-4-yl)-1h-indole-5-carbonyl]-amino}-3-(phenylpyridin-2-yl-amino)-propionic acid as an ikb kinase inhibitor

1999
- 1999-10-26 DE DE19951360A patent/DE19951360A1/de not_active Withdrawn
2000
- 2000-10-17 CA CA2389165A patent/CA2389165C/en not_active Expired - Fee Related
- 2000-10-17 ES ES00974405T patent/ES2329871T3/es not_active Expired - Lifetime
- 2000-10-17 HR HR20020357A patent/HRP20020357B1/xx not_active IP Right Cessation
- 2000-10-17 KR KR1020027005395A patent/KR100795709B1/ko not_active Expired - Fee Related
- 2000-10-17 RS YUP-217/02A patent/RS50424B/sr unknown
- 2000-10-17 CZ CZ2002-1413A patent/CZ304885B6/cs not_active IP Right Cessation
- 2000-10-17 ME MEP-2008-655A patent/ME00434B/me unknown
- 2000-10-17 HU HU0203228A patent/HU229215B1/hu not_active IP Right Cessation
- 2000-10-17 SK SK543-2002A patent/SK287116B6/sk not_active IP Right Cessation
- 2000-10-17 PT PT00974405T patent/PT1261601E/pt unknown
- 2000-10-17 EP EP00974405A patent/EP1261601B1/de not_active Expired - Lifetime
- 2000-10-17 WO PCT/EP2000/010210 patent/WO2001030774A1/de not_active Ceased
- 2000-10-17 DK DK00974405T patent/DK1261601T3/da active
- 2000-10-17 RU RU2002113651/04A patent/RU2255087C2/ru not_active IP Right Cessation
- 2000-10-17 EE EEP200200217A patent/EE05036B1/xx not_active IP Right Cessation
- 2000-10-17 TR TR2002/01144T patent/TR200201144T2/xx unknown
- 2000-10-17 BR BRPI0015026-6A patent/BR0015026B1/pt not_active IP Right Cessation
- 2000-10-17 AT AT00974405T patent/ATE437867T1/de active
- 2000-10-17 CN CNB008144729A patent/CN1172929C/zh not_active Expired - Fee Related
- 2000-10-17 PL PL354528A patent/PL200115B1/pl unknown
- 2000-10-17 JP JP2001533128A patent/JP3843012B2/ja not_active Expired - Fee Related
- 2000-10-17 DE DE50015700T patent/DE50015700D1/de not_active Expired - Lifetime
- 2000-10-17 IL IL14927200A patent/IL149272A0/xx active IP Right Grant
- 2000-10-17 MX MXPA02003998A patent/MXPA02003998A/es active IP Right Grant
- 2000-10-17 SI SI200031041T patent/SI1261601T1/sl unknown
- 2000-10-17 AU AU12728/01A patent/AU781553B2/en not_active Ceased
- 2000-10-17 NZ NZ518587A patent/NZ518587A/en not_active IP Right Cessation
2002
- 2002-04-17 NO NO20021808A patent/NO323952B1/no not_active IP Right Cessation
- 2002-04-22 IL IL149272A patent/IL149272A/en not_active IP Right Cessation
- 2002-04-23 ZA ZA200203204A patent/ZA200203204B/en unknown
- 2002-10-04 US US10/263,691 patent/US20030119820A1/en not_active Abandoned
2004
- 2004-05-11 US US10/842,427 patent/US20040209868A1/en not_active Abandoned
2005
- 2005-07-22 US US11/187,396 patent/US7342029B2/en not_active Expired - Fee Related
2009
- 2009-10-26 CY CY20091101115T patent/CY1110521T1/el unknown

Also Published As

Publication number	Publication date
US20050282866A1 (en)	2005-12-22
AU1272801A (en)	2001-05-08
HU229215B1 (en)	2013-09-30
ZA200203204B (en)	2002-10-23
PL200115B1 (pl)	2008-12-31
US20030119820A1 (en)	2003-06-26
CZ304885B6 (cs)	2015-01-07
EE200200217A (et)	2003-06-16
EE05036B1 (et)	2008-06-16
BR0015026A (pt)	2002-07-16
ATE437867T1 (de)	2009-08-15
NZ518587A (en)	2004-06-25
CA2389165A1 (en)	2001-05-03
SK287116B6 (sk)	2009-12-07
RS50424B (sr)	2009-12-31
ME00434B (me)	2011-10-10
CZ20021413A3 (cs)	2002-07-17
EP1261601A1 (de)	2002-12-04
ES2329871T3 (es)	2009-12-02
TR200201144T2 (tr)	2003-02-21
SK5432002A3 (en)	2002-11-06
NO20021808D0 (no)	2002-04-17
JP3843012B2 (ja)	2006-11-08
MXPA02003998A (es)	2002-10-23
IL149272A0 (en)	2002-11-10
CN1172929C (zh)	2004-10-27
AU781553B2 (en)	2005-05-26
DE19951360A1 (de)	2001-05-03
US20040209868A1 (en)	2004-10-21
HUP0203228A3 (en)	2004-01-28
DE50015700D1 (de)	2009-09-10
HRP20020357A2 (en)	2004-02-29
CA2389165C (en)	2010-11-16
CN1379772A (zh)	2002-11-13
DK1261601T3 (da)	2009-11-16
NO20021808L (no)	2002-04-17
KR20030004302A (ko)	2003-01-14
NO323952B1 (no)	2007-07-23
JP2003519101A (ja)	2003-06-17
US7342029B2 (en)	2008-03-11
HRP20020357B1 (hr)	2010-10-31
KR100795709B1 (ko)	2008-01-21
EP1261601B1 (de)	2009-07-29
PT1261601E (pt)	2009-10-15
SI1261601T1 (sl)	2009-12-31
YU21702A (sh)	2004-11-25
RU2255087C2 (ru)	2005-06-27
HK1049671A1 (zh)	2003-05-23
HUP0203228A2 (hu)	2003-02-28
IL149272A (en)	2007-02-11
WO2001030774A1 (de)	2001-05-03
CY1110521T1 (el)	2015-04-29
BR0015026B1 (pt)	2011-11-29

Publication	Publication Date	Title
IL149272A0 (en)	2002-11-10	Substituted indoles for modulating nfkb activity
PL352399A1 (en)	2003-08-25	Substituted benzimidazoles
MY131298A (en)	2007-08-30	5-heteroyl indole derivatives
MY140074A (en)	2009-11-30	INDOLE DERIVATIVES OR BENZIMIDAZOLE DERIVATIVES FOR MODULATING IkB KINASE
MY121294A (en)	2006-01-28	Novel hexanoic acid derivatives.
MY119403A (en)	2005-05-31	Novel compounds with analgesic effect.
IL112539A0 (en)	1995-05-26	Pyrimidine derivatives and their preparation
AU5377698A (en)	1998-07-03	Substituted pyrrolyl compounds for the treatment of inflammation
AU5485698A (en)	1998-06-29	Oxyiminopregnancarbolactone
CY2473B1 (en)	2005-06-03	New phenanthridines.
IT1285770B1 (it)	1998-06-18	Composti corticoidei
SE9802208D0 (sv)	1998-06-22	Novel compounds
MY133125A (en)	2007-10-31	Novel dihydroxyhexanoic acid derivatives
AU2284001A (en)	2001-07-09	Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone
MY133107A (en)	2007-10-31	Use of pyrimidine derivatives for the prophylaxis and therapy of cerebral ischemia
MX9403088A (es)	1997-02-28	Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
IL150125A0 (en)	2002-12-01	Novel compounds
AU2002332488A1 (en)	2004-02-25	R-bambuterol, its preparation and therapeutic uses
TR200002203T2 (tr)	2000-12-21	Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
SE9802209D0 (sv)	1998-06-22	Novel compounds
AU2002211493A1 (en)	2002-05-15	Indole derivatives as pde5-inhibitors
NZ515531A (en)	2004-03-26	Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods
SE9802207D0 (sv)	1998-06-22	Novel compounds
ZA9810361B (en)	1999-11-12	Heterocyclic compounds having MMP and TNF inhibitory activity.
MX9302644A (es)	1994-06-30	Nuevos enantiomeros derivados de (s)-2-amino-2-(3-4-diclorobencil)-1-propanol-